StockMacro
Menu

LENZ Therapeutics

$2.96 -62% in 6 monthsMarket cap $93.2M

LENZ on XNAS, Health Care, LENZ Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Quarterly revenue fell 73% to $3.4M while the stock fell 89% in 12 months and insiders sold $9.1M.

  • BadShort interest at 23% of shares, 5.6 days to cover
  • WatchCash of $197.3M sits against a $140.3M net loss over 12 months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
152
Website
lenz-tx.com
Listed
Nasdaq, US
Last results
28 Oct 2026
Next results
expected around 6 Jan 2027 (an estimate: a year ago it reported on 7 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $3.4M, net loss $31.0M.
Quarter to 31 Dec 2021: revenue –, net income -$18.9MQuarter to 31 Mar 2022: revenue –, net income -$25.8MQuarter to 30 Jun 2022: revenue –, net income -$25.9MQuarter to 30 Sep 2022: revenue –, net income -$24.7MQuarter to 31 Dec 2022: revenue –, net income -$24.6MQuarter to 31 Mar 2023: revenue –, net income -$23.9MQuarter to 30 Jun 2023: revenue –, net income -$55.3MQuarter to 30 Sep 2023: revenue –, net income -$22.5MQuarter to 31 Dec 2023: revenue –, net income -$22.9MQuarter to 31 Mar 2024: revenue –, net income -$16.6MQuarter to 30 Jun 2024: revenue $0, net income -$10.3MQuarter to 30 Jun 2024: revenue $0, net income -$10.3MQuarter to 30 Sep 2024: revenue $0, net income -$10.2MQuarter to 30 Sep 2024: revenue $0, net income -$10.2MQuarter to 31 Mar 2025: revenue $0, net income -$14.6MQuarter to 31 Mar 2025: revenue $0, net income -$14.6MQuarter to 30 Jun 2025: revenue $5.0M, net income -$14.9MQuarter to 30 Jun 2025: revenue $5.0M, net income -$14.9MQuarter to 30 Sep 2025: revenue $12.5M, net income -$16.7MQuarter to 30 Sep 2025: revenue $12.5M, net income -$16.7MQuarter to 31 Dec 2025: revenue $1.6M, net income -$35.9MQuarter to 31 Dec 2025: revenue $1.6M, net income -$35.9MQuarter to 31 Mar 2026: revenue $1.9M, net income -$41.5MQuarter to 31 Mar 2026: revenue $1.9M, net income -$41.5MQuarter to 30 Jun 2026: revenue $5.5M, net income -$31.9MQuarter to 30 Jun 2026: revenue $5.5M, net income -$31.9MQuarter to 30 Sep 2026: revenue $3.4M, net income -$31.0MQuarter to 30 Sep 2026: revenue $3.4M, net income -$31.0M
31 Dec 2021RevenueNet incomeNet losstallest bar $55.3M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$3.4M-$31.0M
30 Jun 2026$5.5M-$31.9M
31 Mar 2026$1.9M-$41.5M
31 Dec 2025$1.6M-$35.9M
30 Sep 2025$12.5M-$16.7M
30 Jun 2025$5.0M-$14.9M
31 Mar 2025$0-$14.6M
30 Sep 2024$0-$10.2M
30 Jun 2024$0-$10.3M
31 Mar 2024–-$16.6M
31 Dec 2023–-$22.9M
30 Sep 2023–-$22.5M
30 Jun 2023–-$55.3M
31 Mar 2023–-$23.9M
31 Dec 2022–-$24.6M
30 Sep 2022–-$24.7M
30 Jun 2022–-$25.9M
31 Mar 2022–-$25.8M
31 Dec 2021–-$18.9M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $12.4M –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$140.3M -$58.9M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$4.53 $0.32
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 82.0% – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -72.7% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $197.3M $202.2M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$197.3M (net cash) -$202.2M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $6.11
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 7.5 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.49 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
LENZ TherapeuticsLENZ (this company) $93.2Mloss7.5––
Outlook TherapeuticsOTLK $94.9Mloss–––
Voyager TherapeuticsVYGR $95.2Mloss3.8-21%-416%
Zura BioZURA $89.6Mloss–––
Fate TherapeuticsFATE $111.8Mloss23.5-33%–
Armata PharmaceuticalsARMP $112.7Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$9.1M

bought $0, sold $9.1M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-2.8%

137 13F filers vs 141

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

97%

30.6M shares held by 13F filers (30 Sep 2026) of 31.4M outstanding (28 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

23%

7.1M shares sold short (30 Oct 2026) of 31.4M outstanding (28 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

5.6

7.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-22%

9.1M shares sold short in the report before, 7.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

63%

63% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 57%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-73%

$3.4M vs $12.5M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

4

4 articles in the last 7 days; its usual week has 1.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

2.7×

4 articles in the last 7 days; its usual week has 1.5.

Price $2.96 on 20 Nov 2026, -89% over 12 months (12-month range $2.96 to $31.94)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $8.8M in the last 12 months (the 12 months before: -$66.6M).
Revenue per quarter. Revenue $3.4M in the latest quarter, -73% on a year earlier.
Capital spending per quarter. Capital spending $16K in the latest quarter, -93% on a year earlier.
Institutional holders (13F filers). 137 13F filers reported holding it in the latest 13F quarter, -13% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
28 Oct 20268-K and other filingsDirector or officer change
28 Oct 20268-K and other filingsRestructuring costs announced
28 Oct 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Jul 20268-K and other filingsDirector or officer change
2 Jul 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 Mar 2026Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 366K)
16 Dec 2025Sharp changeShort interest spike: short interest spike, 8.0M vs usual 3.4M (2025-11-28); 3.5x the same period a year earlier
2 Dec 2025Sharp changeShort interest spike: short interest spike, 8.6M vs usual 3.3M (2025-11-14); 3.9x the same period a year earlier
18 Nov 2025Sharp changeShort interest spike: short interest spike, 7.2M vs usual 3.0M (2025-10-31); 3.5x the same period a year earlier
2 Sep 2025Sharp changeShort interest spike: short interest spike, 4.8M vs usual 2.5M (2025-08-15); 2.3x the same period a year earlier
11 Sep 20248-K and other filingsRegistered new securities for sale (S-1)
8 Apr 20248-K and other filingsRegistered new securities for sale (S-1)
29 Mar 20248-K and other filingsRegistered new securities for sale (S-1)
22 Mar 20248-K and other filingsDirector or officer change
22 Mar 20248-K and other filingsChanged its auditor
22 Mar 20248-K and other filingsCompleted an acquisition or asset sale
22 Mar 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Nov 20238-K and other filingsDirector or officer change
23 Aug 20238-K and other filingsDirector or officer change
23 Aug 20238-K and other filingsRestructuring costs announced
15 Aug 2023Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 5.6M vs usual 1.0M (2023-06-30); 4.1x the same period a year earlier
2 Aug 20238-K and other filingsDirector or officer change
23 Jun 20238-K and other filingsDirector or officer change
23 Jun 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Mar 20238-K and other filingsDirector or officer change
22 Feb 20238-K and other filingsDirector or officer change
22 Feb 20238-K and other filingsRestructuring costs announced
22 Feb 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Mar 20228-K and other filingsDirector or officer change
8 Dec 20218-K and other filingsDirector or officer change
8 Dec 2021Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Nov 2021: $2.0M published
Month from 1 Dec 2021: $228K published
Month from 1 Jan 2022: $2.0M published
Month from 1 Apr 2022: $1.8M published
Month from 1 Mar 2024: $15.0M published
Month from 1 May 2024: $551K published
Month from 1 Jun 2025: -$20.3M published
Month from 1 Jul 2025: -$12.6M published
Month from 1 Aug 2025: -$17.7M published
Month from 1 Sep 2025: -$5.7M published
Month from 1 Oct 2025: -$10.4M published
Month from 1 Nov 2025: $28K published
Month from 1 Mar 2026: $366K published
Month from 1 Nov 2026: -$9.1M published
Revenue per quarter
Quarter ended 30 Jun 2024: $0; public on 31 Jul 2025
Quarter ended 30 Sep 2024: $0; public on 6 Nov 2025
Quarter ended 31 Mar 2025: $0; public on 12 May 2026
Quarter ended 30 Jun 2025: $5.0M; public on 31 Jul 2025
Quarter ended 30 Sep 2025: $12.5M; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $1.6M; public on 25 Mar 2026
Quarter ended 31 Mar 2026: $1.9M; public on 12 May 2026
Quarter ended 30 Jun 2026: $5.5M, +9.7% on a year earlier; public on 12 Aug 2026
Quarter ended 30 Sep 2026: $3.4M, -73% on a year earlier; public on 4 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2020: $612K; public on 22 Mar 2022
Quarter ended 31 Mar 2021: $360K; public on 13 May 2022
Quarter ended 31 Dec 2021: $981K, +60% on a year earlier; public on 22 Mar 2022
Quarter ended 31 Mar 2022: $3.3M, +809% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $1.4M, +82% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $915K, -75% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $1.0M, +4.1% on a year earlier; public on 21 Mar 2023
Quarter ended 31 Mar 2023: $383K, -88% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $5.6M, +305% on a year earlier; public on 15 Aug 2023
Quarter ended 30 Sep 2023: $4.8M, +426% on a year earlier; public on 14 Nov 2023
Quarter ended 31 Mar 2024: $0, -100% on a year earlier; public on 9 May 2024
Quarter ended 31 Mar 2025: $110K; public on 8 May 2025
Quarter ended 30 Jun 2025: $240K; public on 31 Jul 2025
Quarter ended 30 Sep 2025: $439K; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $38K; public on 25 Mar 2026
Quarter ended 31 Mar 2026: $18K, -84% on a year earlier; public on 12 May 2026
Quarter ended 30 Jun 2026: $16K, -93% on a year earlier; public on 12 Aug 2026
Institutional holders (13F filers)
31 Mar 2024 report: 54; public on 15 May 2024
30 Jun 2024 report: 65; public on 14 Aug 2024
30 Sep 2024 report: 76; public on 14 Nov 2024
31 Dec 2024 report: 91; public on 14 Feb 2025
31 Mar 2025 report: 104; public on 15 May 2025
30 Jun 2025 report: 110; public on 14 Aug 2025
30 Sep 2025 report: 157; public on 14 Nov 2025
31 Dec 2025 report: 155; public on 17 Feb 2026
31 Mar 2026 report: 141; public on 15 May 2026
30 Jun 2026 report: 141; public on 14 Aug 2026
30 Sep 2026 report: 137; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, fiscal year at $19.1M (31 Dec 2025), too little history to compare.
  • Insider net buying (open market): Insiders sold a net $8.8M in the last 12 months (the 12 months before: -$66.6M).
  • Revenue per quarter: Revenue $3.4M in the latest quarter, -73% on a year earlier.
  • Capital spending per quarter: Capital spending $16K in the latest quarter, -93% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 30 insider trades

Last 90 days: 1 sale, $9.1M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
2 Nov 2026Ra Capital Management, L.P. and 3 others10% ownerSell2,718,684$3.36$9.1MForm 4
30 Mar 2026Jeffrey P. GeorgeDirectorBuy5,592$8.92$50KForm 4
30 Mar 2026Daniel R. ChevallardChief Financial OfficerBuy7,500$8.57$64KForm 4
30 Mar 2026Evert B. SchimmelpenninkPresident, CEO and SecretaryBuy28,089$8.95$251KForm 4
19 Nov 2025Shawn OlssonChief Commercial OfficerSellplanned in advance (10b5-1); after exercising options10,000$26.10$261KForm 4
10 Nov 2025James W McCollumDirectorBuy10,500$22.79$239KForm 4
7 Nov 2025Daniel R. ChevallardChief Financial OfficerBuy2,198$22.76$50KForm 4
2 Oct 2025Versant Vantage II GP-GP, LLC and 8 others10% ownerSell224,974$46.01$10.4MForm 4

137 institutions reported shares at the end of Q3 2026, 97% of the shares outstanding; 17 opened a position, 23 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Ra Capital Management, L.P.4.2M13.3%$16.0MNo change
Alpha Wave Global, LP3.6M11.5%$13.9MNo change
BlackRock, Inc.3.4M10.9%$13.2M+1.1M+50%
Versant Venture Management, LLC2.7M8.46%$10.2MNo change
Millennium Management LLC1.2M3.69%$4.5M-348K-23%
Vanguard Capital Management LLC1.1M3.49%$4.2MNo change
72 Investment Holdings, LLC1.0M3.24%$3.9MNo change
Squarepoint Ops LLC967K3.08%$3.7M-780K-45%
Blue Owl Capital Holdings LP782K2.49%$3.0M+25K+3.3%
Two Sigma Investments, LP715K2.27%$2.7M+429K+150%

Company events

All 31 company events

In 12 months: 2 director or officer changes, 1 restructuring. Results releases and routine reports are left out.

FiledWhat happenedSource
28 Oct 2026Director or officer change; Restructuring costs announced8-K
2 Jul 2026Director or officer change8-K
4 Apr 2025Signed a major agreement8-K
11 Sep 2024Registered new securities for sale (S-1)S-1
15 Jul 2024Signed a major agreementSame filing: sold shares privately8-K
8 Apr 2024Registered new securities for sale (S-1)S-1/A
29 Mar 2024Registered new securities for sale (S-1)S-1
21 Mar 2024Director or officer change; Completed an acquisition or asset sale; Changed its auditorSame filing: sold shares privately, changed shareholder rights, change of control, changed its bylaws or fiscal year8-K

The 5 newest of 114 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 28 Oct 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 28 Oct 2026Filings record

    Director or officer change

  3. 28 Oct 2026Filings record

    Restructuring costs announced

  4. 2 Jul 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 2 Jul 2026Filings record

    Director or officer change

  6. 31 Mar 2026Insiders change

    had 3 insiders buy $366K of its shares on the open market within 30 days (3 filings).

    Who bought: Schimmelpennink Evert B., Chevallard Daniel R., George Jeffrey P..

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $366K
    Window
    1 Mar 2026 to 31 Mar 2026

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  7. 31 Mar 2026Insiders record

    George Jeffrey P. (director) bought 5,592 shares of LENZ ($49,881) (dated 30 Mar 2026)

  8. 31 Mar 2026Insiders record

    Chevallard Daniel R. (Chief Financial Officer) bought 7,500 shares of LENZ ($64,275) (dated 30 Mar 2026)

  9. 31 Mar 2026Insiders record

    Schimmelpennink Evert B. (President, CEO and Secretary) bought 28,089 shares of LENZ ($251,397) (dated 30 Mar 2026)

  10. 10 Dec 2025Short interest and volume change

    had 8.0M shares sold short in the 28 Nov 2025 report, 3.5× the same report last year.

    Same report last year: 2.3M; its normal report is 3.4M.

    See the evidence
    This period
    8.0M (the 28 Nov 2025 report)
    Normal report (median of 24 earlier)
    3.4M
    Typical spread (median absolute deviation)
    837K
    How far from its usual level
    +3.7
    Same report last year
    2.3M
    History used
    610 days
    2024-11-29: 2.3M2024-12-13: 2.3M2024-12-31: 2.5M2025-01-15: 2.5M2025-01-31: 2.5M2025-02-14: 2.6M2025-02-28: 2.5M2025-03-14: 2.6M2025-03-31: 2.5M2025-04-15: 2.9M2025-04-30: 3.2M2025-05-15: 3.4M2025-05-30: 3.3M2025-06-13: 3.4M2025-06-30: 3.7M2025-07-15: 3.8M2025-07-31: 3.8M2025-08-15: 4.8M2025-08-29: 5.0M2025-09-15: 5.0M2025-09-30: 5.3M2025-10-15: 5.7M2025-10-31: 7.2M2025-11-14: 8.6M2025-11-28: 8.0M
    the 28 Nov 2025 report24 earlier reportsnormal: 3.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 26 Nov 2025Short interest and volume change

    had 8.6M shares sold short in the 14 Nov 2025 report, 3.9× the same report last year.

    Same report last year: 2.2M; its normal report is 3.3M.

    See the evidence
    This period
    8.6M (the 14 Nov 2025 report)
    Normal report (median of 24 earlier)
    3.3M
    Typical spread (median absolute deviation)
    744K
    How far from its usual level
    +4.8
    Same report last year
    2.2M
    History used
    596 days
    2024-11-15: 2.2M2024-11-29: 2.3M2024-12-13: 2.3M2024-12-31: 2.5M2025-01-15: 2.5M2025-01-31: 2.5M2025-02-14: 2.6M2025-02-28: 2.5M2025-03-14: 2.6M2025-03-31: 2.5M2025-04-15: 2.9M2025-04-30: 3.2M2025-05-15: 3.4M2025-05-30: 3.3M2025-06-13: 3.4M2025-06-30: 3.7M2025-07-15: 3.8M2025-07-31: 3.8M2025-08-15: 4.8M2025-08-29: 5.0M2025-09-15: 5.0M2025-09-30: 5.3M2025-10-15: 5.7M2025-10-31: 7.2M2025-11-14: 8.6M
    the 14 Nov 2025 report24 earlier reportsnormal: 3.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 13 Nov 2025Short interest and volume change

    had 7.2M shares sold short in the 31 Oct 2025 report, 3.5× the same report last year.

    Same report last year: 2.1M; its normal report is 3.0M.

    See the evidence
    This period
    7.2M (the 31 Oct 2025 report)
    Normal report (median of 24 earlier)
    3.0M
    Typical spread (median absolute deviation)
    607K
    How far from its usual level
    +4.7
    Same report last year
    2.1M
    History used
    582 days
    2024-10-31: 2.1M2024-11-15: 2.2M2024-11-29: 2.3M2024-12-13: 2.3M2024-12-31: 2.5M2025-01-15: 2.5M2025-01-31: 2.5M2025-02-14: 2.6M2025-02-28: 2.5M2025-03-14: 2.6M2025-03-31: 2.5M2025-04-15: 2.9M2025-04-30: 3.2M2025-05-15: 3.4M2025-05-30: 3.3M2025-06-13: 3.4M2025-06-30: 3.7M2025-07-15: 3.8M2025-07-31: 3.8M2025-08-15: 4.8M2025-08-29: 5.0M2025-09-15: 5.0M2025-09-30: 5.3M2025-10-15: 5.7M2025-10-31: 7.2M
    the 31 Oct 2025 report24 earlier reportsnormal: 3.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 11 Nov 2025Insiders record

    MCCOLLUM JAMES W (director) bought 10,500 shares of LENZ ($239,295) (dated 10 Nov 2025)

  14. 8 Nov 2025Insiders record

    Chevallard Daniel R. (Chief Financial Officer) bought 2,198 shares of LENZ ($50,025) (dated 7 Nov 2025)

  15. 27 Aug 2025Short interest and volume change

    had 4.8M shares sold short in the 15 Aug 2025 report, 2.3× the same report last year.

    Same report last year: 2.1M; its normal report is 2.5M.

    See the evidence
    This period
    4.8M (the 15 Aug 2025 report)
    Normal report (median of 24 earlier)
    2.5M
    Typical spread (median absolute deviation)
    430K
    How far from its usual level
    +3.6
    Same report last year
    2.1M
    History used
    505 days
    2024-08-15: 2.1M2024-08-30: 2.0M2024-09-13: 1.9M2024-09-30: 1.9M2024-10-15: 2.0M2024-10-31: 2.1M2024-11-15: 2.2M2024-11-29: 2.3M2024-12-13: 2.3M2024-12-31: 2.5M2025-01-15: 2.5M2025-01-31: 2.5M2025-02-14: 2.6M2025-02-28: 2.5M2025-03-14: 2.6M2025-03-31: 2.5M2025-04-15: 2.9M2025-04-30: 3.2M2025-05-15: 3.4M2025-05-30: 3.3M2025-06-13: 3.4M2025-06-30: 3.7M2025-07-15: 3.8M2025-07-31: 3.8M2025-08-15: 4.8M
    the 15 Aug 2025 report24 earlier reportsnormal: 2.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 11 Sep 2024Filings record

    Registered new securities for sale (S-1)

  17. 16 May 2024Insiders record

    Chevallard Daniel R. (Chief Financial Officer) bought 3,188 shares of LENZ ($49,988) (dated 15 May 2024)

  18. 15 May 2024Insiders record

    MCCOLLUM JAMES W (director) bought 31,332 shares of LENZ ($500,999) (dated 14 May 2024)

  19. 8 Apr 2024Filings record

    Registered new securities for sale (S-1)

  20. 29 Mar 2024Filings record

    Registered new securities for sale (S-1)

  21. 26 Mar 2024Insiders record

    RA Capital Nexus Fund II, L.P. (director) and 4 other(s) bought 998,009 shares of LENZ ($15.0M) (dated 25 Mar 2024)

  22. 22 Mar 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  23. 22 Mar 2024Filings record

    Director or officer change (dated 21 Mar 2024)

  24. 22 Mar 2024Filings record

    Changed its auditor (dated 21 Mar 2024)

  25. 22 Mar 2024Filings record

    Completed an acquisition or asset sale (dated 21 Mar 2024)

  26. 15 Nov 2023Filings record

    Director or officer change

  27. 23 Aug 2023Filings record

    Director or officer change

  28. 23 Aug 2023Filings record

    Restructuring costs announced

  29. 15 Aug 2023Financials change

    spent $5.6M on capital projects in the quarter ended 30 Jun 2023, 4.1× the same quarter last year.

    Same quarter last year: $1.4M; its normal quarter is $1.0M.

    See the evidence
    This period
    $5.6M (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    $1.0M
    Typical spread (median absolute deviation)
    $311K
    How far from its usual level
    +4.6
    Same quarter last year
    $1.4M
    History used
    1,003 days
    2021-06-30: $763K2021-09-30: $3.6M2021-12-31: $981K2022-03-31: $3.3M2022-06-30: $1.4M2022-09-30: $915K2022-12-31: $1.0M2023-03-31: $383K2023-06-30: $5.6M
    the quarter ended 30 Jun 20238 earlier quartersnormal: $1.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  30. 2 Aug 2023Filings record

    Director or officer change

  31. 23 Jun 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 23 Jun 2023Filings record

    Director or officer change

  33. 16 Mar 2023Filings record

    Director or officer change

  34. 22 Feb 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 22 Feb 2023Filings record

    Director or officer change

  36. 22 Feb 2023Filings record

    Restructuring costs announced

  37. 14 Apr 2022Insiders record

    Gutry Phil (CHIEF BUSINESS OFFICER) bought 5,000 shares of GRPH ($20,050) (dated 13 Apr 2022)

  38. 14 Apr 2022Insiders record

    AKKARAJU SRINIVAS (ten percent owner) and 1 other(s) bought 424,464 shares of GRPH ($1.7M) (dated 13 Apr 2022)

  39. 2 Mar 2022Filings record

    Director or officer change

  40. 26 Jan 2022Insiders record

    AKKARAJU SRINIVAS (ten percent owner) and 1 other(s) bought 123,000 shares of GRPH ($1.1M) (dated 25 Jan 2022)

Showing the newest 40 of 57 entries; narrow the window or the kind of data to see older ones.

Not listed: 77 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001815776
Ticker
LENZ
Domain
lenz-tx.com
Hq location
CA|SOLANA BEACH|92075 (1 unverified)
Name
Graphite Bio, Inc., LENZ Netherlands B.V, LENZ Therapeutics, Inc., LENZ Therapeutics Operations, Inc
  • SEC Form 13F institutional holdings99 data points31 Mar 2024 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)91 records19 Mar 2021 to 3 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)385 data points31 Dec 2019 to 28 Oct 2026
  • SEC Form 4 insider transactions30 records, 96 data points1 Jul 2021 to 2 Nov 2026
  • FINRA short interest (twice monthly)189 data points28 Mar 2024 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)1340 data points22 Mar 2024 to 20 Nov 2026